Metastatic extramammary Paget's disease responding to weekly paclitaxel

Vania Phuoc, Axel F Grothey

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Metastatic extramammary Paget's disease (EMPD) is a rare cancer with no validated systemic treatment. Regimens including FECOM 5-fluorouracil (5-FU, epirubicin, carboplatin, vincristine and mitomycin C), 5-FU/cisplatin and single agent docetaxel exhibited varying levels of efficacy in case reports. A 58-year-old man with EMPD diffusely metastatic to bone presented with worsening shortness of breath, significant pancytopenia and disseminated intravascular coagulation (DIC). He was started on low-dose heparin for the DIC and weekly paclitaxel. Initially requiring almost daily transfusions, his shortness of breath improved after two doses of paclitaxel, and he became transfusionindependent after only three doses. Correlating with his disease course, the patient's prepaclitaxel carcinoembryonic antigen level of 62.1 ng/mL decreased to 7.4 ng/mL on 3-month follow-up, and he showed no progression of disease on imaging. With no validated chemotherapy regimen currently, this case can help guide consideration of paclitaxel in future treatment of metastatic EMPD.

Original languageEnglish (US)
Article numberA604
JournalBMJ Case Reports
Volume2015
DOIs
StatePublished - Apr 22 2015

Fingerprint

Extramammary Paget's Disease
Paclitaxel
Fluorouracil
Disseminated Intravascular Coagulation
docetaxel
Dyspnea
Epirubicin
Pancytopenia
Carboplatin
Carcinoembryonic Antigen
Mitomycin
Vincristine
Cisplatin
Disease Progression
Heparin
Bone and Bones
Drug Therapy
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Metastatic extramammary Paget's disease responding to weekly paclitaxel. / Phuoc, Vania; Grothey, Axel F.

In: BMJ Case Reports, Vol. 2015, A604, 22.04.2015.

Research output: Contribution to journalArticle

Phuoc, Vania ; Grothey, Axel F. / Metastatic extramammary Paget's disease responding to weekly paclitaxel. In: BMJ Case Reports. 2015 ; Vol. 2015.
@article{5ba99b18f96b4dc6b9a437e2bf8d8193,
title = "Metastatic extramammary Paget's disease responding to weekly paclitaxel",
abstract = "Metastatic extramammary Paget's disease (EMPD) is a rare cancer with no validated systemic treatment. Regimens including FECOM 5-fluorouracil (5-FU, epirubicin, carboplatin, vincristine and mitomycin C), 5-FU/cisplatin and single agent docetaxel exhibited varying levels of efficacy in case reports. A 58-year-old man with EMPD diffusely metastatic to bone presented with worsening shortness of breath, significant pancytopenia and disseminated intravascular coagulation (DIC). He was started on low-dose heparin for the DIC and weekly paclitaxel. Initially requiring almost daily transfusions, his shortness of breath improved after two doses of paclitaxel, and he became transfusionindependent after only three doses. Correlating with his disease course, the patient's prepaclitaxel carcinoembryonic antigen level of 62.1 ng/mL decreased to 7.4 ng/mL on 3-month follow-up, and he showed no progression of disease on imaging. With no validated chemotherapy regimen currently, this case can help guide consideration of paclitaxel in future treatment of metastatic EMPD.",
author = "Vania Phuoc and Grothey, {Axel F}",
year = "2015",
month = "4",
day = "22",
doi = "10.1136/bcr-2014-208653",
language = "English (US)",
volume = "2015",
journal = "BMJ Case Reports",
issn = "1757-790X",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Metastatic extramammary Paget's disease responding to weekly paclitaxel

AU - Phuoc, Vania

AU - Grothey, Axel F

PY - 2015/4/22

Y1 - 2015/4/22

N2 - Metastatic extramammary Paget's disease (EMPD) is a rare cancer with no validated systemic treatment. Regimens including FECOM 5-fluorouracil (5-FU, epirubicin, carboplatin, vincristine and mitomycin C), 5-FU/cisplatin and single agent docetaxel exhibited varying levels of efficacy in case reports. A 58-year-old man with EMPD diffusely metastatic to bone presented with worsening shortness of breath, significant pancytopenia and disseminated intravascular coagulation (DIC). He was started on low-dose heparin for the DIC and weekly paclitaxel. Initially requiring almost daily transfusions, his shortness of breath improved after two doses of paclitaxel, and he became transfusionindependent after only three doses. Correlating with his disease course, the patient's prepaclitaxel carcinoembryonic antigen level of 62.1 ng/mL decreased to 7.4 ng/mL on 3-month follow-up, and he showed no progression of disease on imaging. With no validated chemotherapy regimen currently, this case can help guide consideration of paclitaxel in future treatment of metastatic EMPD.

AB - Metastatic extramammary Paget's disease (EMPD) is a rare cancer with no validated systemic treatment. Regimens including FECOM 5-fluorouracil (5-FU, epirubicin, carboplatin, vincristine and mitomycin C), 5-FU/cisplatin and single agent docetaxel exhibited varying levels of efficacy in case reports. A 58-year-old man with EMPD diffusely metastatic to bone presented with worsening shortness of breath, significant pancytopenia and disseminated intravascular coagulation (DIC). He was started on low-dose heparin for the DIC and weekly paclitaxel. Initially requiring almost daily transfusions, his shortness of breath improved after two doses of paclitaxel, and he became transfusionindependent after only three doses. Correlating with his disease course, the patient's prepaclitaxel carcinoembryonic antigen level of 62.1 ng/mL decreased to 7.4 ng/mL on 3-month follow-up, and he showed no progression of disease on imaging. With no validated chemotherapy regimen currently, this case can help guide consideration of paclitaxel in future treatment of metastatic EMPD.

UR - http://www.scopus.com/inward/record.url?scp=84930619978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930619978&partnerID=8YFLogxK

U2 - 10.1136/bcr-2014-208653

DO - 10.1136/bcr-2014-208653

M3 - Article

C2 - 25903204

AN - SCOPUS:84930619978

VL - 2015

JO - BMJ Case Reports

JF - BMJ Case Reports

SN - 1757-790X

M1 - A604

ER -